Rathbones Group PLC Sells 224,058 Shares of Johnson & Johnson (NYSE:JNJ)

Rathbones Group PLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 18.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 983,260 shares of the company’s stock after selling 224,058 shares during the quarter. Rathbones Group PLC’s holdings in Johnson & Johnson were worth $142,199,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of JNJ. IFS Advisors LLC lifted its position in Johnson & Johnson by 138.9% in the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. WealthTrak Capital Management LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson during the fourth quarter worth about $29,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth about $32,000. Finally, Conquis Financial LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at approximately $33,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Down 4.3 %

Shares of JNJ stock opened at $153.03 on Monday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a market cap of $368.77 billion, a PE ratio of 23.01, a P/E/G ratio of 2.56 and a beta of 0.49. The stock’s fifty day moving average price is $159.75 and its two-hundred day moving average price is $155.76.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.29 earnings per share. Equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of recent research reports. Citigroup reduced their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Barclays increased their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Stifel Nicolaus lowered their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research report on Thursday, January 23rd. Bank of America raised their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research note on Wednesday, March 5th. Finally, Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $171.33.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.